AbbVie Inc. (ABBV) Return on Invested Capital (ROIC): 12.97%
Is AbbVie Inc.’s return on invested capital (ROIC) high or low?
AbbVie Inc.'s return on invested capital (ROIC) of 12.97% is 16% above its 5-year average of 11.16%, near the high end of its 5-year range (8.70%–14.02%).
The return on invested capital (ROIC) for AbbVie Inc. (ABBV) is 12.97% as of Wednesday, June 10, 2026. It is above its 12-month average by 18.88% (10.91%).
ABBV Return on Invested Capital (ROIC) Chart
ABBV Average Return on Invested Capital (ROIC) Chart
ABBV Current vs Average Return on Invested Capital (ROIC) Chart
ABBV Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
12.97%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
10.91%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
11.35%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
11.16%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
12.04%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
14.85%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
13.98%
CURRENT VS TTM AVG
+18.88%
CURRENT VS 3Y AVG
+14.27%
CURRENT VS 5Y AVG
+16.24%
CURRENT VS 10Y AVG
+7.70%
CURRENT VS 15Y AVG
-12.68%
CURRENT VS 20Y AVG
-7.22%
ABBV Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | $399.54B | 12.97% | 10.91% | 11.35% | 11.16% |
| UnitedHealth Group Incorporated (UNH) | $368.44B | 8.23% | 10.28% | 12.20% | 12.63% |
| Merck & Co., Inc. (MRK) | $293.02B | 18.27% | 18.62% | 14.12% | 12.73% |
| Johnson & Johnson (JNJ) | $574.15B | 13.71% | 13.73% | 14.10% | 13.87% |
| Amgen Inc. (AMGN) | $183.75B | 13.16% | 11.04% | 11.80% | 12.80% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 7.58% | 7.80% | 8.16% | 9.10% |
| Abbott Laboratories (ABT) | $154.66B | 8.43% | 9.16% | 9.70% | 9.86% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 21.53% | 11.95% | 11.58% | 9.92% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 13.71% | 12.85% | 12.25% | 11.92% |
| Pfizer Inc. (PFE) | $146.36B | 8.84% | 9.06% | 10.60% | 10.43% |
Capital Efficiency
ROIC
13.0%
ROE
13.2%
AbbVie Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AbbVie Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for AbbVie Inc. (ABBV)?
- The return on invested capital (ROIC) for ABBV stock is 12.97%.
- Is AbbVie Inc.'s return on invested capital (ROIC) high or low?
- AbbVie Inc.'s return on invested capital (ROIC) of 12.97% is 16% above its 5-year average of 11.16%, near the high end of its 5-year range (8.70%–14.02%).
- What is the TTM average return on invested capital (ROIC) for AbbVie Inc. (ABBV)?
- The TTM average return on invested capital (ROIC) for ABBV stock is 10.91%.
- What is the 3Y average return on invested capital (ROIC) for AbbVie Inc. (ABBV)?
- The 3Y average return on invested capital (ROIC) for ABBV stock is 11.35%.
- What is the 5Y average return on invested capital (ROIC) for AbbVie Inc. (ABBV)?
- The 5Y average return on invested capital (ROIC) for ABBV stock is 11.16%.
- What is the 10Y average return on invested capital (ROIC) for AbbVie Inc. (ABBV)?
- The 10Y average return on invested capital (ROIC) for ABBV stock is 12.04%.
- What is the 15Y average return on invested capital (ROIC) for AbbVie Inc. (ABBV)?
- The 15Y average return on invested capital (ROIC) for ABBV stock is 14.85%.
- What is the 20Y average return on invested capital (ROIC) for AbbVie Inc. (ABBV)?
- The 20Y average return on invested capital (ROIC) for ABBV stock is 13.98%.
AbbVie Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 12.97% |
| 2024-12-31 | 8.85% |
| 2023-12-31 | 9.56% |
| 2022-12-31 | 14.02% |
| 2021-12-31 | 12.85% |
| 2020-12-31 | 8.70% |
| 2019-12-31 | 15.71% |
| 2018-12-31 | 13.46% |
| 2017-12-31 | 10.83% |
| 2016-12-31 | 12.43% |
| 2015-12-31 | 13.09% |
| 2014-12-31 | 12.42% |
| 2013-12-31 | 19.27% |
| 2012-12-31 | 25.19% |
| 2011-12-31 | 24.84% |
| 2010-12-31 | 23.46% |
| 2009-12-31 | 0.00% |
Related Metrics
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael